News
The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback